Gloria Huang, ASCO 2019 – NRG Oncology/Gynecologic Oncology Group 210 trial
Gloria Huang discusses results from the NRG Oncology/Gynecologic Oncology Group 210 trial at the ASCO 2019 annual meeting. The trial investigates sex hormone, insulin and insulin-like growth factor signaling in the recurrence of high stage endometrial cancer.
Questions
1. What is known about the role of sex hormone, insulin and insulin-like growth factor (IGF) axis signalling pathways in the development of endometrial cancer? (0:03)
2. What evidence exists for the use of metformin as a treatment for endometrial cancer? (0:44)
3. What other methods of targeting sex hormone, insulin and IGF axis signalling pathways appear promising? (1:27)
4. What were the findings of your study investigating these pathways in the recurrence of high-stage endometrial cancer? (2:41)
5. What are the clinical implications of these findings? (3:33)
Speaker disclosure: Gloria Huang has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
